Estimated prevalence of FVIII-binding Ig isotypes and IgG subclass antibodies with confirmed FVIII specificity
| Cohort . | Sample Size (n) . | IgG1* (%) . | IgG2† (%) . | IgG3* (%) . | IgG4† (%) . | IgA* (%) . | IgM† (%) . |
|---|---|---|---|---|---|---|---|
| nsHA | 81 | 32.1 | 0.0 | 1.2 | 1.2 | 21.0 | 0.0 |
| sHA | 39 | 17.9 | 0.0 | 5.1 | 0.0 | 10.3 | 0.0 |
| healthy | 90 | 5.6 | 0.0 | 2.2 | 0.0 | 5.6 | 0.0 |
| Cohort . | Sample Size (n) . | IgG1* (%) . | IgG2† (%) . | IgG3* (%) . | IgG4† (%) . | IgA* (%) . | IgM† (%) . |
|---|---|---|---|---|---|---|---|
| nsHA | 81 | 32.1 | 0.0 | 1.2 | 1.2 | 21.0 | 0.0 |
| sHA | 39 | 17.9 | 0.0 | 5.1 | 0.0 | 10.3 | 0.0 |
| healthy | 90 | 5.6 | 0.0 | 2.2 | 0.0 | 5.6 | 0.0 |
See Table 1 for definitions.
Estimated prevalences of FVIII-binding IgG1, IgG3, and IgA antibodies with proven FVIII specificity are highlighted in bold.
Only patients with FVIII-specific IgG1, IgG3, and IgA titers ≥1:40 were considered.
Only patients with FVIII-specific IgG2, IgG4, and IgM titers ≥1:80 were considered.